Minerva Neurosciences (NERV) Expected to Announce Quarterly Earnings on Thursday

Minerva Neurosciences (NASDAQ:NERV) is anticipated to post its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Minerva Neurosciences to post earnings of ($1.05) per share for the quarter.

Minerva Neurosciences Price Performance

Shares of NERV stock opened at $1.85 on Thursday. Minerva Neurosciences has a 12 month low of $1.80 and a 12 month high of $9.40. The firm has a market capitalization of $12.93 million, a P/E ratio of -4.20 and a beta of 0.12. The company’s fifty day moving average price is $2.20 and its two-hundred day moving average price is $2.43.

Analysts Set New Price Targets

Several research firms have recently weighed in on NERV. StockNews.com began coverage on shares of Minerva Neurosciences in a research report on Friday, February 14th. They issued a “sell” rating for the company. HC Wainwright reissued a “neutral” rating and issued a $5.00 target price on shares of Minerva Neurosciences in a research report on Wednesday, November 6th.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.